The FDA just recently approved first time treatment for patients struggling from Barth Syndrome, a rare life-threatening disease which affects the mitochondria, powerhouse of the cell.

Barth Syndrome mainly affects males and often begins in infancy with severe heart failure, leading to high chances of early death. Those who make it to adolescence & adulthood, commonly experience fatigue, low stamina and difficulty with physical activity. Leaving patients with reduced quality of life.

Forzinity works by binding to the inner mitochondrial membrane, helping improve mitochondrial structure and function. The FDA granted its accelerated approval, a pathway that allows earlier access to treatments for serious conditions with limited options. This decision was based on evidence showing improved strength in the quadriceps muscle, which is important for straightening the knee and is considered likely to lead to meaningful benefits, such as standing up more easily or walking further. As a condition of this approval, the manufacturer must conduct a post-approval randomized, double-blind, placebo-controlled trial, to confirm that the muscle strength improvements translate into real benefits for patients.

Forzinity is given once daily as a subcutaneous (under the skin) injection. In clinical trials, the most common side effects were mild to moderate reactions at the injection site, though serious adverse events have also been reported. The application received priority review and was designated as a rare pediatric disease therapy.

Learn more: FDA Grants Accelerated Approval to First Treatment for Barth Syndrome | FDA